[go: up one dir, main page]

RU2017125688A - ANTI-VIRUS PHARMACEUTICAL COMPOSITION - Google Patents

ANTI-VIRUS PHARMACEUTICAL COMPOSITION Download PDF

Info

Publication number
RU2017125688A
RU2017125688A RU2017125688A RU2017125688A RU2017125688A RU 2017125688 A RU2017125688 A RU 2017125688A RU 2017125688 A RU2017125688 A RU 2017125688A RU 2017125688 A RU2017125688 A RU 2017125688A RU 2017125688 A RU2017125688 A RU 2017125688A
Authority
RU
Russia
Prior art keywords
pharmaceutical composition
presented
antiviral pharmaceutical
composition according
virus pharmaceutical
Prior art date
Application number
RU2017125688A
Other languages
Russian (ru)
Other versions
RU2017125688A3 (en
RU2701514C2 (en
Inventor
Юрий Захарович Толчеев
Вадим Алексеевич Козловский
Original Assignee
Юрий Захарович Толчеев
Вадим Алексеевич Козловский
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юрий Захарович Толчеев, Вадим Алексеевич Козловский filed Critical Юрий Захарович Толчеев
Publication of RU2017125688A3 publication Critical patent/RU2017125688A3/ru
Publication of RU2017125688A publication Critical patent/RU2017125688A/en
Application granted granted Critical
Publication of RU2701514C2 publication Critical patent/RU2701514C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/731—Carrageenans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/04—Rhodophycota or rhodophyta (red algae), e.g. Porphyra
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (4)

1. Противовирусная фармацевтическая композиция, содержащая бета-глюкан, преимуществено в виде карбоксиметил бета-глюкана натриевой соли, и йотта-каррагенан в весовом соотношении от приблизительно 1 к 0,5 до приблизительно 1 к 5.1. An antiviral pharmaceutical composition comprising beta-glucan, preferably in the form of sodium carboxymethyl beta-glucan, and iotta-carrageenan in a weight ratio of from about 1 to 0.5 to about 1 to 5. 2. Противовирусная фармацевтическая композиция по п. 1, отличающаяся тем, что представлена в виде аэрозоля для доставки посредством дозирующего ингалятора в виде назального или вагинального спрея.2. The antiviral pharmaceutical composition according to claim 1, characterized in that it is presented in the form of an aerosol for delivery by means of a metered dose inhaler in the form of a nasal or vaginal spray. 3. Противовирусная фармацевтическая композиция по п. 1, отличающаяся тем, что представлена в виде порошка для инсуффляций в полости тела.3. The antiviral pharmaceutical composition according to claim 1, characterized in that it is presented in the form of a powder for insufflation in the body cavity. 4. Противовирусная фармацевтическая композиция по п. 1, отличающаяся тем, что представлена в виде геля.4. The antiviral pharmaceutical composition according to claim 1, characterized in that it is presented in the form of a gel.
RU2017125688A 2015-10-22 2016-10-24 Antiviral pharmaceutical composition RU2701514C2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
UAA201510327A UA118192C2 (en) 2015-10-22 2015-10-22 ANTI-VIRUS PHARMACEUTICAL COMPOSITION
UAA201510327 2015-10-22
PCT/UA2016/000122 WO2017069721A1 (en) 2015-10-22 2016-10-24 Antiviral pharmaceutical composition

Publications (3)

Publication Number Publication Date
RU2017125688A3 RU2017125688A3 (en) 2019-01-23
RU2017125688A true RU2017125688A (en) 2019-01-23
RU2701514C2 RU2701514C2 (en) 2019-09-27

Family

ID=64604286

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017125688A RU2701514C2 (en) 2015-10-22 2016-10-24 Antiviral pharmaceutical composition

Country Status (4)

Country Link
EA (1) EA036809B1 (en)
RU (1) RU2701514C2 (en)
UA (1) UA118192C2 (en)
WO (1) WO2017069721A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018222581A1 (en) * 2017-05-29 2018-12-06 Resinnate Therapeutics Llc Methods and formulations for administering beta glucan
JP7179764B2 (en) * 2017-06-07 2022-11-29 ソシエテ・デ・プロデュイ・ネスレ・エス・アー A powdery thickener that retains its elongation properties when reconstituted and aids in safe swallowing by dysphagic individuals
LT3773501T (en) * 2018-03-29 2024-01-10 The Materia Company Limited INTRAVAGINAL PREPARATION
SE546142C2 (en) * 2020-04-03 2024-06-11 Liw Innovation Ab New compositions for oral use
GB202109888D0 (en) 2021-07-08 2021-08-25 Pollinner Ltd Nasal spray

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1273576A (en) 1987-09-16 1990-09-04 Patrick A. Beauchamp Topical treatment for diseased skin disorders
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
ITMI20032067A1 (en) 2003-10-23 2005-04-24 Unihart Corp SPRAY FORMULATION FOR THE TREATMENT OF VIRAL INFECTIONS.
US20060165623A1 (en) * 2005-01-24 2006-07-27 Terra Firma Natuals, Inc. Natural deodorant composition
US20080131454A1 (en) * 2006-12-05 2008-06-05 Marinomed Biotechnologie Gmbh Methods and Compositions for the Treatment of Rhinovirus Infections with Carrageenan
DE602007005697D1 (en) * 2006-12-05 2010-05-12 Marinomed Biotechnologie Gmbh USE OF CARRAGEENAN FOR THE TREATMENT OF RHINOVIRUS INFECTIONS
IT1393272B1 (en) 2009-02-20 2012-04-12 D M G Italia S R L PHARMACEUTICAL COMPOSITION CONTAINING MICROCOLLOIDAL SILVER AND CARBOSSIMETHYLBETHAGLAN FOR DISINFECTION OF NASAL MUCOSA AND ITS PREPARATION PROCEDURE

Also Published As

Publication number Publication date
RU2017125688A3 (en) 2019-01-23
WO2017069721A1 (en) 2017-04-27
UA118192C2 (en) 2018-12-10
EA036809B1 (en) 2020-12-23
EA201800266A1 (en) 2018-09-28
RU2701514C2 (en) 2019-09-27

Similar Documents

Publication Publication Date Title
Zhou et al. Emerging inhalation aerosol devices and strategies: where are we headed?
RU2017125688A (en) ANTI-VIRUS PHARMACEUTICAL COMPOSITION
PH12016500433A1 (en) Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
CY1120605T1 (en) DRY POWDER PREPARATION INCLUDING A PHOSPHODIESTERATION INHIBITOR
PH12020551709A1 (en) Antiviral immunotropic agent for the treatment of acute respiratory viral infections
MX2017003102A (en) Liquid inhalation formulation comprising rpl554.
PH12015502539A1 (en) Cenicriviroc compositions and methods of making and using the same
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
MX369803B (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases.
EA201591869A1 (en) COMPOSITION CONTAINING TO IMPROVE THE STABILITY OF THE MEDICINE FORM AT A LESS THEME OF TWO DRY POWDER RECEIVED BY SPRAY DRYING
MY165888A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
WO2016044839A3 (en) Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
MX2015015132A (en) Inhalable pharmaceutical compositions and the inhaler devices containing them.
EP2682102A3 (en) Inhalation Compositions Comprising Corticosteroid and Sorbitol
EP2682101A3 (en) Inhalation Compositions Comprising Glucose Anhydrous
MY191712A (en) Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation
EP2682098A3 (en) Inhalation Compositions
MX2017013950A (en) Zolmitriptan powders for pulmonary delivery.
WO2011093815A3 (en) Pharmaceutical compositions comprising formoterol and mometasone
MX2015015150A (en) Inhalable pharmaceutical compositions and the inhaler devices containing them.
PH12017500538A1 (en) Inhalation device
WO2011093811A3 (en) Pharmaceutical preparations comprising formoterol and fluticasone
MX2017001900A (en) Nasal composition comprising mixture of hyaluronic acids and saline solution.
WO2011093812A3 (en) Pharmaceutical formulation comprising tiotropium and budesonide in dry powder form
LV15003A (en) A pharmaceutical composition for the control of weight gain